S

Seagen Inc
F:SGT

Watchlist Manager
Seagen Inc
F:SGT
Watchlist
Price: 208.6 EUR Market Closed
Market Cap: 39.4B EUR
Have any thoughts about
Seagen Inc?
Write Note

Seagen Inc
Goodwill

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Seagen Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
S
Seagen Inc
F:SGT
Goodwill
$274.7m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.3B
CAGR 3-Years
3%
CAGR 5-Years
18%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.1B
CAGR 3-Years
3%
CAGR 5-Years
19%
CAGR 10-Years
43%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology

Seagen Inc. is a leading biotechnology company focused on developing innovative therapies for cancer treatment using its pioneering antibody-drug conjugate (ADC) technology. Founded in 1998, Seagen's mission is rooted in the belief that targeted therapies can improve the lives of cancer patients. The company has gained attention in the oncology space with its flagship products, such as Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin), which target specific cancer cells while minimizing damage to healthy tissue. This approach not only enhances efficacy but also helps in reducing side effects commonly associated with traditional chemotherapy. With a strong pipeline of investigational therapies that leverage their ADC platform, Seagen is positioned to be a transformative player in the oncology market. For investors, Seagen represents a compelling opportunity within the biotech sector, especially as demand for effective cancer treatments continues to grow. The company is actively expanding its product portfolio through strategic partnerships and collaborations, bolstering its capabilities in research and development. Financially, Seagen has demonstrated solid sales growth driven by its approved products, and it is continually working towards regulatory approvals for its pipeline candidates. As the landscape of cancer treatment evolves and personalized medicine becomes increasingly important, Seagen's innovative approach and commitment to delivering better patient outcomes make it a company to watch for those interested in the future of oncology and of the broader biotechnology market.

SGT Intrinsic Value
147.22 EUR
Overvaluation 29%
Intrinsic Value
Price
S

See Also

What is Seagen Inc's Goodwill?
Goodwill
274.7m USD

Based on the financial report for Sep 30, 2023, Seagen Inc's Goodwill amounts to 274.7m USD.

What is Seagen Inc's Goodwill growth rate?
Goodwill CAGR 5Y
2%

Over the last year, the Goodwill growth was 0%.

Back to Top